InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
Penny Roger$ Free
03/04/12 6:26 AM
profile icon
richrichrich Free
02/22/12 8:38 PM
profile icon
trustyrusty4 Free
02/22/12 5:39 PM
profile icon
richrichrich Free
02/17/12 8:46 PM
profile icon
Pepperoni Free
02/17/12 2:21 PM
profile icon
richrichrich Free
02/07/12 9:33 PM
profile icon
missionsman Free
01/13/12 12:07 PM
profile icon
fcpgalltheway Free
01/11/12 9:09 AM
profile icon
missionsman Free
01/10/12 3:38 PM
profile icon
RomeZ Free
01/10/12 3:23 PM
profile icon
surf1944 Free
01/10/12 11:35 AM
profile icon
BullsEye Free
01/10/12 11:06 AM
profile icon
BullsEye Free
01/10/12 9:40 AM
profile icon
BobEye Free
01/09/12 8:22 PM
profile icon
missionsman Free
01/08/12 11:21 PM
profile icon
buzz lightyear Free
01/08/12 3:52 PM
profile icon
$tockfather Free
01/08/12 3:43 PM
profile icon
surf1944 Free
01/08/12 11:53 AM
profile icon
Talc Moan Free
01/08/12 10:22 AM
profile icon
mlkrborn Free
01/08/12 9:07 AM
profile icon
Pennyprof Free
01/08/12 8:10 AM
profile icon
BullsEye Free
12/20/11 11:52 AM
profile icon
surf1944 Free
12/16/11 11:03 AM
profile icon
BullsEye Free
12/16/11 10:56 AM
profile icon
mlkrborn Free
12/16/11 10:48 AM
profile icon
MiamiGent PremiumMember
12/16/11 10:12 AM
profile icon
surf1944 Free
12/16/11 9:22 AM
profile icon
DAD2 Free
12/16/11 8:45 AM
profile icon
surf1944 Free
12/13/11 11:16 AM
profile icon
BullsEye Free
12/02/11 10:33 AM
profile icon
BullsEye Free
12/01/11 1:38 PM
profile icon
$tockfather Free
12/01/11 1:12 PM
profile icon
BullsEye Free
12/01/11 12:48 PM
profile icon
$tockfather Free
12/01/11 10:55 AM
profile icon
surf1944 Free
12/01/11 10:07 AM
profile icon
$tockfather Free
12/01/11 10:02 AM
profile icon
BullsEye Free
12/01/11 10:00 AM
profile icon
$tockfather Free
11/30/11 2:24 PM
profile icon
BullsEye Free
11/30/11 12:29 PM
profile icon
$tockfather Free
11/29/11 10:33 AM
profile icon
BullsEye Free
11/29/11 9:31 AM
profile icon
BullsEye Free
11/29/11 9:28 AM
profile icon
BullsEye Free
11/29/11 9:25 AM

Inhibitex, Inc. (INHX) RSS Feed

Followers
7
Posters
45
Posts (Today)
0
Posts (Total)
219
Created
11/15/06
Type
Free
Moderators
http://www.inhibitex.com/

http://finance.yahoo.com/q?s=INHX

http://finance.google.com/finance?client=ob&q=INHX


Inhibitex, Inc., a development stage company, engages in the discovery, development, and commercialization of novel antibody based products for bacterial and fungal hospital-associated infections. The company has two product candidates in clinical development stage, which comprise Veronate, a Phase III development stage product, for the prevention of certain hospital-associated infections in premature and very low birth weight infants; and Aurexis, which completed Phase II trial, to treat Staphylococcus aureus, bloodstream infections in hospitalized patients. It also has four product candidates in preclinical development that are based on the use of MSCRAMM proteins. These products include staphylococcus epidermidis monoclonal antibodies, for the prevention of coagulase negative staphylococci; enterococcal monoclonal antibodies, for the treatment of hospital-associated enterococcal infections; candida monoclonal antibodies to treat hospital-associated candida infections; and staphylococcal vaccine, for the prevention of staphylococcal infections. Inhibitex has collaboration and joint development agreement with Dyax Corp. to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines. The company was founded in 1994 and is based in Alpharetta, Georgia.


Overview

We are a biopharmaceutical company focused on the discovery, development and commercialization of novel antibody-based products for the prevention and treatment of serious bacterial and fungal infections in the hospital setting.
We currently have two product candidates in clinical development and four product candidates in preclinical development. Our product candidates have been developed based upon our expertise in MSCRAMM® proteins, for which we own or have licensed numerous patents and patent applications. MSCRAMM® proteins are located on the surface of pathogenic organisms, such as bacteria and fungi, and play a prominent role in the process of infection. These proteins enable organisms to initiate and maintain an infection by adhering to specific sites on human tissue or implanted medical devices. Our antibody-based product candidates are designed to bind to specific MSCRAMM® proteins, thereby reducing the incidence and severity of infections.

Our lead product candidate, Veronate®, is being developed for the prevention of hospital-associated infections in premature, very low birth weight (VLBW) infants. We have completed the enrollment phase of a 2,000 patent pivotal Phase III trial of Veronate®, and we anticipate data from this trial to be available in the second quarter of 2006. Veronate® has been granted both Fast Track and Orphan Drug status by the FDA and has been designated an orphan medicinal product by the EMEA in Europe. Our second product candidate, Aurexis®, is being evaluated in clinical trials as a first-line therapy, in combination with standard of care antibiotics, to treat serious Staphylococcus aureus (S. aureus) bloodstream infections in hospitalized patients.

We have retained world-wide commercialization rights to both Veronate® and Aurexis®, and expect to commercialize Veronate® in the United States by establishing a specialized, hospital-based sales force. While we expect to establish a worldwide collaboration for Aurexis®, we anticipate retaining co-promotion rights to Aurexis® in the United States. In markets outside the United States, we intend to enter into collaborations to develop and commercialize our product candidates.

We believe there is a substantial opportunity to utilize our expertise in MSCRAMM® proteins to discover, develop and commercialize novel antibody-based products that address the increasing prevalence of serious life-threatening hospital-associated infections and the lack of effective therapies available to treat these infections.

>
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
INHX Latest News
  • No Recent News Available for this company!
New Post